Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2026)

Bioventus' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $650.5 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 5.91% year-over-year to $650.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 8.0% YoY) and the FY2025 annual result came in at $683.6 million, down 6.1% from the prior year.
• Liabilities and Shareholders Equity was $650.5 million for Q1 2026 at Bioventus, down from $683.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2022 and bottomed at $650.5 million in Q1 2026.
• A 5-year average of $884.7 million and a median of $794.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 113.51% — and 2023, when it slumped 41.98%.
• Bioventus' Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then slumped by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 6.1% to $683.6 million in 2025, then retreated by 4.83% to $650.5 million in 2026.
• Business Quant data shows BVS's Liabilities and Shareholders Equity at $650.5 million in Q1 2026, $683.6 million in Q4 2025, and $701.6 million in Q3 2025.